BRPI0818201A2 - Composto de azolcarboxamida ou sal do mesmo - Google Patents

Composto de azolcarboxamida ou sal do mesmo

Info

Publication number: BRPI0818201A2
Authority: BR; Brazil
Prior art keywords: azolcarboxamide; salt composite; composite; salt
Prior art date: 2007-10-24

Application number

Other languages

English (en)

Inventor

Keizo Sugasawa

Kenichi Kawaguchi

Takaho Nomura

Shunichiro Matsumoto

Takashi Shin

Hidenori Azami

Tomoaki Abe

Akira Suga

Ryushi Seo

Masayuki Tanahashi

Toru Watanabe

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-24

Filing date

2008-10-23

Publication date

2015-04-22

2008-10-23 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2015-04-22 Publication of BRPI0818201A2 publication Critical patent/BRPI0818201A2/pt

2019-01-29 Publication of BRPI0818201B1 publication Critical patent/BRPI0818201B1/pt

2021-05-25 Publication of BRPI0818201B8 publication Critical patent/BRPI0818201B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

BRPI0818201A 2007-10-24 2008-10-23 composto de azolcarboxamida ou sal do mesmo e uso do mesmo para o tratamento de frequência urinária, urgência urinária, incontinência urinária e dores do trato urinário inferior associadas com várias doenças do trato urinário inferior, e várias doenças acompanhadas de dor BRPI0818201B8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2007276894		2007-10-24
PCT/JP2008/069263 WO2009054468A1 (ja)	2007-10-24	2008-10-23	アゾールカルボキサミド化合物又はその塩

Publications (3)

Publication Number	Publication Date
BRPI0818201A2 true BRPI0818201A2 (pt)	2015-04-22
BRPI0818201B1 BRPI0818201B1 (pt)	2019-01-29
BRPI0818201B8 BRPI0818201B8 (pt)	2021-05-25

Family

ID=40579570

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0818201A BRPI0818201B8 (pt)	2007-10-24	2008-10-23	composto de azolcarboxamida ou sal do mesmo e uso do mesmo para o tratamento de frequência urinária, urgência urinária, incontinência urinária e dores do trato urinário inferior associadas com várias doenças do trato urinário inferior, e várias doenças acompanhadas de dor

Country Status (21)

Country	Link
US (1)	US8304547B2 (pt)
EP (1)	EP2206707B1 (pt)
JP (1)	JP5321467B2 (pt)
KR (1)	KR101504787B1 (pt)
CN (1)	CN101835764B (pt)
AU (1)	AU2008314922B2 (pt)
BR (1)	BRPI0818201B8 (pt)
CA (1)	CA2703106C (pt)
CY (1)	CY1115547T1 (pt)
DK (1)	DK2206707T3 (pt)
ES (1)	ES2498065T3 (pt)
HR (1)	HRP20140970T1 (pt)
IL (1)	IL205071A (pt)
MX (1)	MX2010004499A (pt)
PL (1)	PL2206707T3 (pt)
PT (1)	PT2206707E (pt)
RU (1)	RU2461551C2 (pt)
SI (1)	SI2206707T1 (pt)
TW (1)	TWI418557B (pt)
WO (1)	WO2009054468A1 (pt)
ZA (1)	ZA201002608B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3623374B1 (en)	2008-12-03	2021-09-08	The Scripps Research Institute	Stem cell cultures
ES2545795T3 (es) *	2009-04-09	2015-09-15	Cognition Therapeutics, Inc.	Inhibidores del deterioro cognitivo
CN102595884B (zh)	2009-07-31	2014-12-03	考格尼申治疗股份有限公司	认知衰退的抑制剂
AU2010291834A1 (en) *	2009-09-04	2012-03-15	Zalicus Pharmaceuticals Ltd.	Substituted heterocyclic derivatives for the treatment of pain and epilepsy
SG178986A1 (en) *	2009-09-08	2012-04-27	Hoffmann La Roche	4-substituted pyridin-3-yl-carboxamide compounds and methods of use
JP2012254939A (ja) *	2009-10-07	2012-12-27	Astellas Pharma Inc	オキサゾール化合物
US9018227B2 (en)	2010-03-19	2015-04-28	Indiana State University	Nicotinic acetylcholine receptor agonists
JP6161537B2 (ja)	2010-04-07	2017-07-12	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物及び使用の方法
EP2635559A2 (en) *	2010-11-01	2013-09-11	Neurotune AG	Neurotrypsin inhibitors
WO2012061926A1 (en) *	2010-11-08	2012-05-18	Zalicus Pharmaceuticals Ltd.	Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
BR112013019775A2 (pt)	2011-02-02	2017-04-18	Cognition Therapeutics Inc	composto, composição farmacêutica e método para tratar declínio cognitivo ou doença de alzheimer em um paciente
MA34969B1 (fr) *	2011-02-25	2014-03-01	Irm Llc	Composes et compositions en tant qu inibiteurs de trk
SI2743348T1 (en)	2011-08-11	2018-04-30	Astellas Pharma Inc.	Novel anti-human ngf antibody
EP2760857A1 (en)	2011-09-27	2014-08-06	F.Hoffmann-La Roche Ag	Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
US20150291514A1 (en) *	2012-01-04	2015-10-15	Pfizer Limted	N-Aminosulfonyl Benzamides
TW201350479A (zh)	2012-04-26	2013-12-16	Ono Pharmaceutical Co	Ｔｒｋ阻害化合物
WO2014081718A1 (en)	2012-11-20	2014-05-30	Genentech, Inc.	Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
EP2961403A4 (en)	2013-03-01	2016-11-30	Zalicus Pharmaceuticals Ltd	HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
GB201313664D0 (en) *	2013-07-31	2013-09-11	Univ Cardiff	Bcl-3 inhibitors
EP3097095A1 (en) *	2014-01-24	2016-11-30	AbbVie Inc.	Furo-3-carboxamide derivatives and methods of use
RU2692258C2 (ru)	2014-01-31	2019-06-24	Когнишн Терапьютикс, Инк.	Композиции изоиндолина и способы лечения нейродегенеративного заболевания
US9951060B2 (en)	2014-06-06	2018-04-24	Astellas Pharma Inc.	2-acylaminothiazole derivative or salt thereof
CN106573928B (zh) *	2014-08-26	2020-04-14	安斯泰来制药株式会社	2-氨基噻唑衍生物或其盐
CN114716390A (zh)	2015-04-07	2022-07-08	Ela制药有限公司	用于治疗和/或预防细胞或组织坏死的组合物和方法
LT3286181T (lt) *	2015-04-22	2021-04-26	Rigel Pharmaceuticals, Inc.	Pirazolo junginiai ir junginių gamybos bei naudojimo būdas
CN105601585B (zh) *	2015-12-17	2018-01-05	浙江工业大学	一种含噻唑环的羧酰胺类化合物及其制备与应用
CN108473450B (zh) *	2016-01-01	2022-05-10	阿达玛阿甘股份有限公司	1,1,3-三氧代-1,2-苯并噻唑-6-甲酰胺的制备方法
BR102018007822A2 (pt)	2017-04-20	2018-11-06	Gilead Sciences, Inc.	composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
DK3634394T3 (da)	2017-05-15	2026-03-02	Cognition Therapeutics Inc	Sammensætninger til behandling af neurogenerative sygdomme
CR20200347A (es)	2018-02-13	2020-09-23	Gilead Sciences Inc	Inhibidores pd-1/pd-l1
TWI712412B (zh)	2018-04-19	2020-12-11	美商基利科學股份有限公司	Pd‐1/pd‐l1抑制劑
UA126099C2 (uk)	2018-05-09	2022-08-10	ЕлДжи КЕМ, ЛТД.	Сполука, яка виявляє інгібувальну активність відносно ентеропептидази
SG11202012425QA (en)	2018-07-13	2021-01-28	Gilead Sciences Inc	Pd-1/pd-l1 inhibitors
WO2020086556A1 (en)	2018-10-24	2020-04-30	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
CN109627207A (zh) *	2018-12-17	2019-04-16	天津药明康德新药开发有限公司	一种3-(二氟甲氧基)哌啶盐酸盐的制备方法
EA202192575A1 (ru)	2019-03-21	2022-01-14	Онксео	Соединения dbait в сочетании с ингибиторами киназ для лечения рака
PE20220970A1 (es)	2019-08-30	2022-06-10	Rigel Pharmaceuticals Inc	Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones
KR20220150270A (ko)	2019-10-07	2022-11-10	칼리오페, 인크.	Gpr119 효능제
CN114761006A (zh)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
TW202140440A (zh)	2020-02-28	2021-11-01	美商克力歐普股份有限公司	Gpr40激動劑
WO2021236617A1 (en)	2020-05-19	2021-11-25	Kallyope, Inc.	Ampk activators
CN116390925A (zh)	2020-06-26	2023-07-04	卡尔优普公司	Ampk活化剂
US12357623B2 (en)	2021-03-03	2025-07-15	Rigel Pharmaceuticals, Inc.	Method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202315628A (zh) *	2021-06-24	2023-04-16	南韓商Ｌｇ化學股份有限公司	作為ｒｏｎ抑制劑之新穎吡啶衍生物化合物
EP4159743A1 (en) *	2021-09-30	2023-04-05	ETH Zurich	Methods for preparing pyridazine compounds
IL315677A (en)	2022-03-23	2024-11-01	Rigel Pharmaceuticals Inc	Pyrimid-2-yl-pyrazole compounds as irak inhibitors
KR20250048243A (ko) *	2022-07-07	2025-04-08	리브라 테라퓨틱스, 인크.	옥사졸 trpml1 작용제 및 이의 용도
TW202535364A (zh) *	2024-01-08	2025-09-16	美商利布拉醫療公司	噻唑trpml1促效劑及其用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5395932A (en)	1993-04-30	1995-03-07	G. D. Searle & Co.	2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
GB9424379D0 (en) *	1994-12-02	1995-01-18	Agrevo Uk Ltd	Fungicides
JP2002512633A (ja)	1997-06-26	2002-04-23	イーライ・リリー・アンド・カンパニー	抗血栓剤
ATE299499T1 (de)	1998-11-09	2005-07-15	Black James Foundation	Gastrin und cholecystokinin rezeptor ligande
EP1169038B9 (en) *	1999-04-15	2013-07-10	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
US6399780B1 (en)	1999-08-20	2002-06-04	Cephalon, Inc.	Isomeric fused pyrrolocarbazoles and isoindolones
US6455525B1 (en)	1999-11-04	2002-09-24	Cephalon, Inc.	Heterocyclic substituted pyrazolones
JP2001278872A (ja) *	2000-03-27	2001-10-10	Banyu Pharmaceut Co Ltd	新規アミノチアゾール誘導体
FR2807660A1 (fr)	2000-04-13	2001-10-19	Warner Lambert Co	Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
EP1317446A1 (en)	2000-09-01	2003-06-11	Glaxo Group Limited	Oxindole derivatives
AU2001288374A1 (en)	2000-09-01	2002-03-22	Glaxo Group Limited	Substituted oxindole derivatives as tyrosine kinase inhibitors
HUP0303204A3 (en)	2000-11-16	2010-04-28	Sankyo Co	1-methylcarbapenem derivatives and pharmaceutical compositions containing them
AU2002248432A1 (en)	2001-02-14	2002-08-28	Sankyo Company, Limited	Oxazole derivatives, their preparation and their use as cytokine inhibitors
JP2002338537A (ja)	2001-05-16	2002-11-27	Mitsubishi Pharma Corp	アミド化合物およびその医薬用途
AR034897A1 (es)	2001-08-07	2004-03-24	Hoffmann La Roche	Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
EP1430053B1 (en)	2001-09-27	2006-10-25	SmithKline Beecham Corporation	AZAOXOINDOLE DERIVATIVES AS Trk PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND CHRONIC PAIN
JP2003231687A (ja)	2002-02-04	2003-08-19	Japan Tobacco Inc	ピラゾリル縮合環化合物及びその医薬用途
US20040110802A1 (en) *	2002-08-23	2004-06-10	Atli Thorarensen	Antibacterial benzoic acid derivatives
WO2004071440A2 (en)	2003-02-06	2004-08-26	Bristol-Myers Squibb Company	Thiazolyl-based compounds useful as kinase inhibitors
JP2006517234A (ja) *	2003-02-10	2006-07-20	アムジエン・インコーポレーテツド	バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
DE10306250A1 (de)	2003-02-14	2004-09-09	Aventis Pharma Deutschland Gmbh	Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7223788B2 (en) *	2003-02-14	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
MXPA05011503A (es)	2003-04-25	2006-05-31	Johnson & Johnson	Inhibidores de la c-fms cinasa.
US20050113566A1 (en)	2003-04-25	2005-05-26	Player Mark R.	Inhibitors of C-FMS kinase
US7427683B2 (en)	2003-04-25	2008-09-23	Ortho-Mcneil Pharmaceutical, Inc.	c-fms kinase inhibitors
FR2856685B1 (fr)	2003-06-25	2005-09-23	Merck Sante Sas	Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
WO2005030705A1 (en)	2003-09-24	2005-04-07	Methylgene, Inc.	Inhibitors of histone deacetylase
TW200523252A (en)	2003-10-31	2005-07-16	Takeda Pharmaceutical	Pyridine compounds
JP4869072B2 (ja)	2003-11-14	2012-02-01	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール
MY141220A (en)	2003-11-17	2010-03-31	Astrazeneca Ab	Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005076695A2 (en)	2004-02-11	2005-08-25	Painceptor Pharma Corporation	Methods of modulating neurotrophin-mediated activity
EP1742921A2 (en)	2004-04-21	2007-01-17	AstraZeneca AB	Pyrazole derivatives useful for the treatment of cancer
CA2575466A1 (en)	2004-08-13	2006-02-23	Genentech, Inc.	Thiazole based inhibitors of atp-utilizing enzymes
DE102004039789A1 (de)	2004-08-16	2006-03-02	Sanofi-Aventis Deutschland Gmbh	Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1637529A1 (en) *	2004-09-20	2006-03-22	4Sc Ag	Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US7601745B2 (en) *	2004-09-27	2009-10-13	4Sc Ag	Heterocyclic NF-kB inhibitors
EP1812439B2 (en) *	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinase inhibitors
WO2006044527A1 (en) *	2004-10-15	2006-04-27	Amgen Inc.	Imidazole derivatives as vanilloid receptor ligands
WO2006047504A1 (en)	2004-10-22	2006-05-04	Janssen Pharmaceutica, N.V.	Aromatic amides as inhibitors of c-fms kinase
US20060252807A1 (en)	2005-04-22	2006-11-09	Kalypsys, Inc.	Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
UA92746C2 (en)	2005-05-09	2010-12-10	Акилайон Фармасьютикалз, Инк.	Thiazole compounds and methods of use
WO2007000582A1 (en)	2005-06-28	2007-01-04	Takeda Cambridge Limited	Heterocyclic non-peptide gnrh antagonists
PE20070211A1 (es) *	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7700552B2 (en)	2005-07-29	2010-04-20	Medivir Ab	Macrocyclic inhibitors of hepatitis C virus
AR055203A1 (es)	2005-08-31	2007-08-08	Otsuka Pharma Co Ltd	Derivados de benzotiofeno con propiedades antipsicoticas
AU2006290814B2 (en)	2005-09-13	2012-06-07	Janssen Pharmaceutica N.V.	2-aniline-4-aryl substituted thiazole derivatives
WO2007030939A2 (en)	2005-09-15	2007-03-22	Painceptor Pharma Corporation	Methods of modulating neurotrophin-mediated activity
CA2622960A1 (en) *	2005-09-20	2007-03-29	Merck & Co., Inc.	Niacin receptor agonists, compositions containing such compounds and methods of treatment
CA2628074C (en)	2005-10-25	2014-01-14	Shionogi & Co., Ltd.	Aminodihydrothiazine derivative
US7514435B2 (en)	2005-11-18	2009-04-07	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
KR20080063865A (ko)	2005-11-28	2008-07-07	에프. 호프만-라 로슈 아게	다이아실글리세롤 아실전이효소(ｄｇａｔ)의 저해제
EP1996565A2 (en)	2006-03-08	2008-12-03	Achillion Pharmaceuticals, Inc.	Substituted aminothiazole derivatives with anti-hcv activity
EP1994017A2 (en)	2006-03-15	2008-11-26	4Sc Ag	Novel heterocyclic nf-kb inhibitors
JP5182088B2 (ja) *	2006-04-19	2013-04-10	アステラス製薬株式会社	アゾールカルボキサミド誘導体
CA2659512C (en)	2006-06-06	2015-09-08	Critical Therapeutics, Inc.	Novel piperazines, pharmaceutical compositions and methods of use thereof
GB0614070D0 (en)	2006-07-14	2006-08-23	Glaxo Group Ltd	Compounds
EP1881001A1 (en)	2006-07-20	2008-01-23	Tibotec Pharmaceuticals Ltd.	HCV NS-3 serine protease inhibitors
JP5103604B2 (ja)	2006-10-31	2012-12-19	メルク・シャープ・アンド・ドーム・コーポレーション	プロテインキナーゼ阻害剤としての２−アミノチアゾール−４−カルボン酸アミド
EP2078004B1 (en)	2006-10-31	2015-02-25	Merck Sharp & Dohme Corp.	2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
WO2008054702A1 (en)	2006-10-31	2008-05-08	Schering Corporation	Anilinopiperazine derivatives and methods of use thereof
WO2008059214A1 (en)	2006-11-13	2008-05-22	Astrazeneca Ab	Bisamlde derivatives and use thereof as fatty acid synthase inhibitors

2008
- 2008-10-23 EP EP08842145.8A patent/EP2206707B1/en active Active
- 2008-10-23 JP JP2009538260A patent/JP5321467B2/ja not_active Expired - Fee Related
- 2008-10-23 US US12/739,433 patent/US8304547B2/en not_active Expired - Fee Related
- 2008-10-23 RU RU2010120676/04A patent/RU2461551C2/ru active
- 2008-10-23 CA CA2703106A patent/CA2703106C/en active Active
- 2008-10-23 ES ES08842145.8T patent/ES2498065T3/es active Active
- 2008-10-23 HR HRP20140970AT patent/HRP20140970T1/hr unknown
- 2008-10-23 CN CN2008801138204A patent/CN101835764B/zh not_active Expired - Fee Related
- 2008-10-23 AU AU2008314922A patent/AU2008314922B2/en not_active Ceased
- 2008-10-23 PL PL08842145T patent/PL2206707T3/pl unknown
- 2008-10-23 WO PCT/JP2008/069263 patent/WO2009054468A1/ja not_active Ceased
- 2008-10-23 MX MX2010004499A patent/MX2010004499A/es active IP Right Grant
- 2008-10-23 PT PT88421458T patent/PT2206707E/pt unknown
- 2008-10-23 DK DK08842145.8T patent/DK2206707T3/da active
- 2008-10-23 SI SI200831299T patent/SI2206707T1/sl unknown
- 2008-10-23 BR BRPI0818201A patent/BRPI0818201B8/pt not_active IP Right Cessation
- 2008-10-23 KR KR1020107006536A patent/KR101504787B1/ko not_active Expired - Fee Related
- 2008-10-24 TW TW097140903A patent/TWI418557B/zh not_active IP Right Cessation
2010
- 2010-04-14 ZA ZA2010/02608A patent/ZA201002608B/en unknown
- 2010-04-14 IL IL205071A patent/IL205071A/en active IP Right Grant
2014
- 2014-09-10 CY CY20141100725T patent/CY1115547T1/el unknown

Also Published As

Publication number	Publication date
RU2461551C2 (ru)	2012-09-20
BRPI0818201B1 (pt)	2019-01-29
AU2008314922B2 (en)	2013-08-29
DK2206707T3 (da)	2014-08-11
TWI418557B (zh)	2013-12-11
CN101835764B (zh)	2012-09-19
PT2206707E (pt)	2014-09-25
BRPI0818201B8 (pt)	2021-05-25
WO2009054468A1 (ja)	2009-04-30
ES2498065T3 (es)	2014-09-24
TW200932743A (en)	2009-08-01
CA2703106C (en)	2015-12-01
EP2206707A4 (en)	2011-08-17
KR20100071047A (ko)	2010-06-28
PL2206707T3 (pl)	2015-01-30
AU2008314922A1 (en)	2009-04-30
JP5321467B2 (ja)	2013-10-23
CN101835764A (zh)	2010-09-15
EP2206707A1 (en)	2010-07-14
EP2206707B1 (en)	2014-07-23
US20100249088A1 (en)	2010-09-30
JPWO2009054468A1 (ja)	2011-03-10
IL205071A0 (en)	2010-11-30
CA2703106A1 (en)	2009-04-30
US8304547B2 (en)	2012-11-06
SI2206707T1 (sl)	2014-11-28
RU2010120676A (ru)	2011-11-27
IL205071A (en)	2015-08-31
KR101504787B1 (ko)	2015-03-20
ZA201002608B (en)	2011-07-27
HRP20140970T1 (hr)	2015-01-30
CY1115547T1 (el)	2017-01-04
MX2010004499A (es)	2010-05-20

Publication	Publication Date	Title
BRPI0818201A2 (pt)	2015-04-22	Composto de azolcarboxamida ou sal do mesmo
BRPI0815588A2 (pt)	2015-02-18	Compostos de poliorganossiloxano-poliuréia e/ou de poliorganossilo-xano-poliuretano
DE602008002674D1 (de)	2010-11-04	Lenksystem
DE602008000880D1 (de)	2010-05-12	Lenksystem
BRPI0818380A2 (pt)	2014-10-07	Combinação de herbicida-protetor
BRPI0816278A2 (pt)	2015-09-22	forma sal
DE602008004938D1 (de)	2011-03-31	Fahrzeugaußengriffsystem
EP1998904A4 (en)	2011-09-07	COMPOSITE SCREEN
BRPI0807004A2 (pt)	2014-04-15	Sal
DE602007012976D1 (de)	2011-04-21	Lenksystem
BRPI0920648A2 (pt)	2015-08-25	Combinações pesticidas contendo sulfoxaflor
BRPI0908880A2 (pt)	2018-02-27	sistemas de varredoura
EP2004372A4 (en)	2010-05-05	Composite mandrel
DE602008001653D1 (de)	2010-08-12	Lenksystem
BRPI0811775A2 (pt)	2014-11-11	Compostos de policarbonato -e /ou poliuretano-poliorganossiloxano
EP2242680A4 (en)	2014-06-18	DRIVE SYSTEM
BRPI0920361A2 (pt)	2016-08-02	materiais de compósito melhorados
BRPI0812359A2 (pt)	2015-01-27	Derivado de tetra-hidroisoquinolin-1-ona ou sal do mesmo
DE602008005054D1 (de)	2011-04-07	Ultraschallsystem
BRPI0820446A2 (pt)	2015-05-26	Recipente compósito
DE602008004179D1 (de)	2011-02-10	Motorsteuerungssystem
BRPI0808109A2 (pt)	2014-06-17	Unidade de bagagem
EP2227553A4 (en)	2011-01-19	Lac expression system
BRPI0810566A2 (pt)	2016-11-22	métodos de ativação de transponder
BRPI0818631A2 (pt)	2015-04-07	Cobertura de carril

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-08	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-06-05	B06I	Publication of requirement cancelled [chapter 6.9 patent gazette]
2018-07-03	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-01-02	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-01-29	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/01/2019, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2024-08-13	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A ANUIDADE.
2024-12-03	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2797 DE 13-08-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.